Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM) | Synapse
March 3, 2026
Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)
Key Points
Arlocabtagene autoleucel demonstrates potential effectiveness in treating relapsed/refractory multiple myeloma.
Key evidence includes significant responses observed with arlocabtagene in early trials, showing promise for this patient population.
Phase 2 study design focuses on the safety and efficacy of arlocabtagene autoleucel in patients with RRMM.
Potential for advancing treatment options in multiple myeloma, indicating a need for further investigations.